Login to Your Account



Eteplirsen Wows in DMD, Sarepta Shares Double

By Marie Powers
Staff Writer

Wednesday, August 8, 2012

Sarepta Therapeutics Inc. (formerly AVI BioPharma Inc.) wowed clinicians and investors Tuesday with Phase IIb findings for its exon-skipping compound, eteplirsen, in Duchenne's muscular dystrophy (DMD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription